Αποτελέσματα Αναζήτησης
AC (Adriamycin® + Cyclophosphamide) followed by THP (Taxol® + Herceptin® + Pertuzumab) is a Chemotherapy Regimen for Breast Cancer - early stage. How does AC-THP work? Doxorubicin, cyclophosphamide, and paclitaxel are chemotherapy drugs designed to kill or slow the growth of cancer cells.
- Early Stage
AC (Adriamycin® + Cyclophosphamide) followed by THP...
- Neutropenic Fever
Neutropenia is when you have a low number of infection...
- Early Stage
Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
Cancer treatment can have harmful effects on fertility and this should be discussed with all patients of reproductive potential prior to commencing treatment. There is a risk of foetal harm in pregnant women. A pregnancy test should be considered prior to initiating treatment in females of reproductive potential if sexually active.
26 Απρ 2016 · Less cardiotoxicity is seen with TCH (docetaxel, carboplatin, and trastuzumab) than with AC→TH (doxorubicin and cyclophosphamide→docetaxel and trastuzumab), and TCH is recommended for patients at higher risk for cardiotoxicity.*
Prophylactic G-CSF may be used to mitigate the risk of haematological toxicities. Patients should have an increased fluid intake of 2-3 litres on day 1 to prevent haemorrhagic cystitis associated with cyclophosphamide. Myalgias and arthralgias may occur with PACLitaxel. Analgesic cover should be considered.
14 Δεκ 2023 · Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is present in approximately 15 percent of primary invasive breast cancers [1]. Women with early-stage breast cancer that meet criteria for HER2 positivity are treated with chemotherapy and trastuzumab as adjuvant treatment.
11 Απρ 2024 · Sequential Adriamycin-cyclophosphamide therapy with paclitaxel or docetaxel (AC-T) was declared by a 2015 review to likely be the most effective treatment regimen of early-stage breast cancer regardless of hormone status.
